SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is under pressure amid concerns about declining same-store sales, softer restaurant traffic and constrained consumer spending, compounded by weakness across restaurant stocks and worries about fuel and inflation costs. Traders are split between viewing the steep selloff and fresh lows as a buying opportunity, citing franchise expansion, and expecting further downside as sales momentum weakens.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Updated Phase 3 VIKTORIA-1 data presented at ESMO is driving attention, with traders highlighting the triplet regimens strong progression-free survival results in PIK3CA-mutant breast cancer, especially among patients without liver metastases. The reaction is largely enthusiastic, though some debate how much the subgroup results say about the broader opportunity and note that the FDAs sNDA decision timeline remains unclear.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

BNB is drawing attention mainly for technical price action, with repeated chart posts describing consolidation and traders debating whether a rebound can continue or give way to a deeper pullback. Views are mixed, ranging from bullish calls for a breakout to warnings that rallies may be corrective amid broader crypto-market weakness.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visas upcoming fiscal-year results are drawing attention as the stock trades near record highs after a strong breakout. Traders are split between bullish momentum into the report and concerns that the shares are overbought and vulnerable to a pullback.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on broad-market volatility and the Dows relative performance versus tech-heavy indexes, with traders debating whether blue-chip strength can persist or whether weakening trends point to further declines. Rising Treasury yields and Fed policy, alongside Iran-related oil risks, are recurring concerns, while bullish traders anticipate rebounds.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

Bitwise XRP ETF shares are drawing attention amid optimism over XRP-related ETF demand and regulatory clarity, alongside broader crypto-market momentum. Traders are bullish on potential institutional inflows, while others remain cautious about weak price action and confusion between the ETF and XRP itself.

dogwifhat (WIF) is a Solana-based memecoin featuring a Shiba Inu dog wearing a pink knitted hat that has become a central figure in the 2024-2026 market. Originally launched anonymously in late 2023, the project operates on a decentralized, community-driven model with no formal venture capital backing or complex tokenomics. It represents a cultural phenomenon on the Solana blockchain that celebrates whimsy and simplicity over technical complexity, focusing on its identity as a playful mascot for the digital finance era. The project’s main value proposition is its "Pure Meme Identity," as it maintains a strict focus on its meme origins without forced utility or a pivot toward DeFi and gaming.  The project embodies the community-driven nature of the Solana ecosystem, prioritizing "vibes" and meme-sharing as its primary growth drivers. It follows a "hat stays on" philosophy, maintaining a singular focus on its core meme rather than building a complex ecosystem. While the project does not have a formal governance structure or DAO, decisions are largely driven by social consensus among the community and key influencers. Notable community initiatives include the "Sphere Wif Hat" campaign, which raised nearly $700,000 in USDC in March 2024 to put the mascot on the Las Vegas Sphere. However, after a year of negotiations and delays, organizers officially abandoned the advertisement on March 31, 2025, and initiated a full refund process for donors.  The initial team behind dogwifhat remains anonymous, which is a standard practice within the memecoin sector. The coin's narrative is heavily influenced by prominent crypto personalities, most notably Ansem, who was a key figure in the project's early viral growth and subsequent marketing initiatives. Regarding integrations, WIF has deep liquidity across major Solana decentralized exchanges like Jupiter and Raydium, is available on the Unichain network via official contract bridging, and is listed on major centralized exchanges including Binance, Coinbase, Kraken, and Bybit.  WIF is a purely speculative asset whose value is primarily driven by community sentiment and meme culture rather than traditional utility. It was launched without a presale or significant venture capital allocation, meaning the token's supply is fully circulating. The project has achieved a "blue chip" status in the memecoin space, often serving as a beta-play for the broader health of the Solana ecosystem. No native decentralized applications or trading bots have been officially launched by the core team, as the project maintains its focus on its identity as "literally a dog wif a hat".

dogwifhat

WIF is drawing attention amid persistent selling and stalled, range-bound trading, with many traders frustrated that brief rebounds fade and the token remains weak. Some see the decline as a buying opportunity and anticipate a recovery, while claims of price manipulation remain speculation.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Phase 1 atopic dermatitis results for Corvuss drug soquelitinib are driving discussion, with bullish traders citing promising efficacy signals and skeptics questioning the limited data and follow-up. The stocks decline despite the results has sparked debate over a sell-the-news reaction versus short-selling pressure.

The Clorox Co. engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States. The Household segments consists of bags and wraps, grilling products and cat litter marketed and sold in the United States. The Lifestyle segment refers to food, natural personal care products and water-filtration products marketed and sold in the United States. The International segment covers products sold outside the United States, excluding natural personal care products. The company was founded by Edward Hughes, Charles Husband, William Hussey, Rufus Myers, and Archibald Taft on May 3, 1913 and is headquartered in Oakland, CA.

Clorox Co.

Cloroxs weaker outlook, declining sales and margin pressure have fueled a sharp selloff and fresh-low concerns. Traders are divided between buying the beaten-down shares for their dividend and long-term value and worrying about continued underperformance, leadership and dividend sustainability.

PENN Entertainment, Inc. engages in the provision of integrated entertainment, sports content, and casino gaming services. It operates through the following business segments: Northeast, South, West, Midwest, Interactive, and Other. The Northeast segment includes Ameristar East Chicago, Hollywood Casino, Hollywood Gaming, Marquee, and Plainridge Park Casino operations. The South segment manages 1st Jackpot Casino, Ameristar Vicksburg, Boomtown, Hollywood Casino Gulf Coast, Hollywood Casino Tunica, L’Auberge, and Margaritaville Resort Casino. The West segment is involved in Ameristar Black Hawk, Cactus Petes and Horseshu, M Resort Spa Casino, and Zia Park Casino operations. The Midwest segment focuses on Ameristar Council Bluffs, Argosy Casino, Hollywood Casino, Prairie State Gaming, and River City Casino operations. The Interactive segment refers to an online gaming portfolio which includes ESPN BET, Hollywood Casino, theScore Bet, and PENN Game Studios. The Other segment consists of stand-alone racing operations, namely Sanford-Orlando Kennel Club, Sam Houston, and Valley Race Park. The company was founded by Peter M. Carlino in 1982 and is headquartered in Wyomissing, PA.

PENN Entertainment Inc

PENN Entertainment Inc.

PENNs steep selloff and upcoming quarterly results are driving discussion, with traders focused on whether the digital betting business can improve and criticizing management over its strategy. Some see the stock as oversold near support and anticipate a rebound, while others remain wary of further losses.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AI, Cancer Vaccines, and Next-Gen Medicine 

Could cancer vaccines and AI drive the next wave of healthcare innovation?

Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough

Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.

Biotech ETF (CANC) Hits New 52-Week High

CANC hits a 52-week high as strong oncology developments and positive momentum fuel the biotech ETF's rally.

Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76%

Equity

H.C. Wainwright expressed optimism about the company’s prospects after Celcuity’s breast cancer therapy achieved its primary endpoint in a Phase 3 trial.

Here's Why Biotech ETFs Are Rallying Hard 

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.

Why Did GLUE Stock Surge Over 50% In Premarket Today?

Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.

Temas Oncology ETF (CANC) Surpasses $100m in Assets Amidst Strong 2025 Performance

Tema ETFs (Tema), the New York-based manager of innovative exchange-traded funds (ETFs), is pleased to announce the Tema Oncology ETF (CANC) has surpassed $100m in assets under management (AUM) two...

Be Thankful to These ETFs This Year 

Be thankful for this year's resilient ETFs -- BWET, LITP, PINK and CANC -- which shined despite volatility, tariffs, AI worries and Fed shifts.

AUTL Stock Soars Pre-market On Positive Recommendation For Cell Therapy Targeting Cancer In UK

NICE has recommended that Aucatzyl be used as a treatment option for adult patients aged 26 years or older with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, the company said. 

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



Tema ETF Trust - Tema Oncology ETF

Neutral Sentiment

<ul class="summary-bullets"><li>H.C. Wainwright upgraded Celcuity to ‘Buy’ from ‘Neutral’ and raised its price target to $165 from $94, citing positive Phase 3 trial results.</li><li>Citizens raised its price target for Celcuity to $160 from $150 and maintained an ‘Outperform’ rating.</li><li>The firm highlighted expected progression-free survival of 11–12 months for the triplet regimen and stronger-than-anticipated efficacy from the doublet versus control.</li></ul>Celcuity Inc. (CELC) could become an acquisition target in the oncology space, according to analysts, after the company reported positive results in the Phase 3 trial of its breast cancer therapy.According to TheFly, analysts at HC Wainwright expressed optimism about the company’s prospects after Celcuity’s breast cancer therapy, gedatolisib, achieved its primary endpoint in a Phase 3 trial.<a href="https://stocktwits.com/symbol/CELC">Celcuity shares</a> were up more than 15% in Monday’s pre-market trade, extending the gains from Friday. If CELC stock ends Monday’s regular trading session with these gains, it would be the stock’s best single-day gain in more than six months.Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Why Are Analysts Optimistic?</h2>Analysts at H.C. Wainwright upgraded Celcuity to ‘Buy’ from ‘Neutral’ and raised their price target to $165 from $94, citing positive Phase 3 trial results. The firm said gedatolisib has the potential to be a “game-changing” treatment for HR+/HER2- advanced breast cancer and could position Celcuity as an acquisition target.Citizens raised its price target for Celcuity to $160 from $150 and maintained an ‘Outperform’ rating. The firm said the data suggest the drug could expand its use in second-line ER+/HER2- advanced breast cancer, demonstrating benefit regardless of PI3K mutation status.It also pointed to expected progression-free survival of 11–12 months for the triplet regimen and stronger-than-anticipated efficacy from the doublet versus control.Stifel analyst Stephen Willey raised the firm’s price target on Celcuity to $150 from $125 and maintained a ‘Buy’ rating. Willey said the “statistically significant and clinically meaningful” improvement in the Phase 3 trial was largely expected, but noted that its selection as a late-breaking oral presentation at the ASCO Annual Meeting on June 2 was the bigger surprise.<h2 class="st-heading-2">Celcuity’s Latest Announcement</h2>Celcuity reported positive Phase 3 results for gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer after prior CDK4/6 and aromatase inhibitor treatment.The company stated that the gedatolisib triplet regimen met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared with alpelisib plus fulvestrant.The gedatolisib doublet also delivered a statistically significant PFS benefit compared with the control arm, despite being a secondary endpoint; both regimens demonstrated manageable safety profiles with no new safety concerns.HR+/HER2- breast cancer is the most common form of the disease, representing about 70% of all cases. Within this group, roughly 40% of patients carry PIK3CA mutations.<a href="https://stocktwits.com/symbol/CELC">CELC stock</a> is up 26% year-to-date and 1,063% over the past 12 months. The Tema Oncology ETF (CANC) is up 50% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 58%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gamestop-ryan-cohen-ebay-build-larger-business-gme-ebay-stock/cZQMpRjReJc">GameStop's Ryan Cohen Says He Plans On Bringing An Entrepreneurial Mindset To eBay And Building Something 'Much Larger'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celcuity logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Tema Oncology ETF

SPDR S&P Biotech ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$41.29
Prev Close	$41.50
Open	$40.83
Dividend Yield	N/A
50-Day Moving Average	$42.20
Beta	N/A
Avg. Volume	28,492.65
PE Ratio	N/A

52-Week High	$47.00
52-Week Low	$30.14
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

CANC Fundamentals